Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 4/2016

01-07-2016 | Original Article

Two novel mutations of CLCN7 gene in Chinese families with autosomal dominant osteopetrosis (type II)

Authors: Hui Zheng, Chong Shao, Yan Zheng, Jin-Wei He, Wen-Zhen Fu, Chun Wang, Zhen-Lin Zhang

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2016

Login to get access

Abstract

Autosomal dominant osteopetrosis type II (ADO-II) is a heritable bone disorder characterized by osteosclerosis, predominantly involving the spine (vertebral end-plate thickening, or rugger-jersey spine), the pelvis (“bone-within-bone” structures) and the skull base. Chloride channel 7 (CLCN7) has been reported to be the causative gene. In this study, we aimed to identify the pathogenic mutation in four Chinese families with ADO-II. All 25 exons of the CLCN7 gene, including the exon–intron boundaries, were amplified and sequenced directly in four probands from the Chinese families with ADO-II. The mutation site was then identified in other family members and 250 healthy controls. In family 1, a known missense mutation c.296A>G in exon 4 of CLCN7 was identified in the proband, resulting in a tyrosine (UAU) to cysteine (UGU) substitution at p.99 (Y99C); the mutation was also identified in his affected father. In family 2, a novel missense mutation c.865G>C in exon 10 was identified in the proband, resulting in a valine (GUC) to leucine (CUC) substitution at p.289 (V289L); the mutation was also identified in her healthy mother and sister. In family 3, a novel missense mutation c.1625C>T in exon 17 of CLCN7 was identified in the proband, resulting in an alanine (GCG) to valine (GUG) substitution at p.542 (A542V); the mutation was also identified in her father. In family 4, a hot spot, R767W (c.2299C>T, CGG>TGG), in exon 24 was found in the proband which once again proved the susceptibility of the site or the similar genetic background in different races. Moreover, two novel mutations, V289L and A542V, occurred at a highly conserved position, found by a comparison of the protein sequences from eight vertebrates, and were predicted to have a pathogenic effect by PolyPhen-2 software, which showed “probably damaging” with a score of approximately 1. These mutation sites were not identified in 250 healthy controls. Our present findings suggest that the novel missense mutations V289L and A542V in the CLCN7 gene were responsible for ADO-II in the two Chinese families.
Literature
1.
go back to reference Johnston CC Jr., Lavy N, Lord T, Vellios F, Merritt AD, Deiss WP Jr (1968) Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine 47:149–167CrossRefPubMed Johnston CC Jr., Lavy N, Lord T, Vellios F, Merritt AD, Deiss WP Jr (1968) Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine 47:149–167CrossRefPubMed
2.
go back to reference Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W (2001) Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861–2867CrossRefPubMed Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W (2001) Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861–2867CrossRefPubMed
3.
go back to reference Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001) Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205–215CrossRefPubMed Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001) Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205–215CrossRefPubMed
4.
go back to reference Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M et al (2003) Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 18:1740–1747CrossRefPubMed Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M et al (2003) Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 18:1740–1747CrossRefPubMed
5.
go back to reference Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V (2003) Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. Hum Genet 112:186–189PubMed Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V (2003) Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. Hum Genet 112:186–189PubMed
6.
go back to reference Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513–1518CrossRefPubMed Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513–1518CrossRefPubMed
7.
go back to reference Letizia C, Taranta A, Migliaccio S, Caliumi C, Diacinti D, Delfini E, D’Erasmo E, Iacobini M, Roggini M, Albagha OM, Ralston SH, Teti A (2004) Type II benign osteopetrosis (Albers-Schonberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations. Calcif Tissue Int 74:42–46CrossRefPubMed Letizia C, Taranta A, Migliaccio S, Caliumi C, Diacinti D, Delfini E, D’Erasmo E, Iacobini M, Roggini M, Albagha OM, Ralston SH, Teti A (2004) Type II benign osteopetrosis (Albers-Schonberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations. Calcif Tissue Int 74:42–46CrossRefPubMed
8.
go back to reference Zhang ZL, He JW, Zhang H, Hu WW, Fu WZ, Gu JM, Yu JB, Gao G, Hu YQ, Li M, Liu YJ (2009) Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab 27:444–451CrossRefPubMed Zhang ZL, He JW, Zhang H, Hu WW, Fu WZ, Gu JM, Yu JB, Gao G, Hu YQ, Li M, Liu YJ (2009) Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab 27:444–451CrossRefPubMed
9.
go back to reference Wang C, Zhang H, He JW, Gu JM, Hu WW, Hu YQ, Li M, Liu YJ, Fu WZ, Yue H, Ke YH, Zhang ZL (2012) The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families. J Bone Miner Metab 30:338–348CrossRefPubMed Wang C, Zhang H, He JW, Gu JM, Hu WW, Hu YQ, Li M, Liu YJ, Fu WZ, Yue H, Ke YH, Zhang ZL (2012) The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families. J Bone Miner Metab 30:338–348CrossRefPubMed
10.
go back to reference Zheng H, Zhang Z, He JW, Fu WZ, Wang C, Zhang ZL (2013) Identification of two novel CLCN7 gene mutations in three Chinese families with autosomal dominant osteopetrosis type II. Joint Bone Spine 81:188–189CrossRefPubMed Zheng H, Zhang Z, He JW, Fu WZ, Wang C, Zhang ZL (2013) Identification of two novel CLCN7 gene mutations in three Chinese families with autosomal dominant osteopetrosis type II. Joint Bone Spine 81:188–189CrossRefPubMed
11.
go back to reference Rashid BM, Rashid NG, Schulz A, Lahr G, Nore BF (2013) A novel missense mutation in the CLCN7 gene linked to benign autosomal dominant osteopetrosis: a case series. J Med Case Rep 7:7CrossRefPubMedPubMedCentral Rashid BM, Rashid NG, Schulz A, Lahr G, Nore BF (2013) A novel missense mutation in the CLCN7 gene linked to benign autosomal dominant osteopetrosis: a case series. J Med Case Rep 7:7CrossRefPubMedPubMedCentral
12.
go back to reference Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249CrossRefPubMedPubMedCentral Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249CrossRefPubMedPubMedCentral
13.
go back to reference Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. Curr Protoc Hum Genet 7:2 Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. Curr Protoc Hum Genet 7:2
14.
go back to reference Sui W, Ou M, Liang J, Ding M, Chen J, Liu W, Xiao R, Meng X, Wang L, Pan X (2013) Rapid gene identification in a Chinese osteopetrosis family by whole exome sequencing. Gene 516:311–315CrossRefPubMed Sui W, Ou M, Liang J, Ding M, Chen J, Liu W, Xiao R, Meng X, Wang L, Pan X (2013) Rapid gene identification in a Chinese osteopetrosis family by whole exome sequencing. Gene 516:311–315CrossRefPubMed
15.
go back to reference Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A et al (2006) Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43:315–325CrossRefPubMed Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A et al (2006) Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43:315–325CrossRefPubMed
16.
go back to reference Wang C, Zhang H, He JW, Gu JM, Hu WW, Hu YQ, Li M, Liu YJ, Fu WZ, Yue H, Ke YH, Zhang ZL (2012) The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families. J Bone Miner Metab 30:338–348CrossRefPubMed Wang C, Zhang H, He JW, Gu JM, Hu WW, Hu YQ, Li M, Liu YJ, Fu WZ, Yue H, Ke YH, Zhang ZL (2012) The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families. J Bone Miner Metab 30:338–348CrossRefPubMed
17.
go back to reference Zhang ZL, He JW, Zhang H, Hu WW, Fu WZ, Gu JM, Yu JB, Gao G, Hu YQ, Li M, Liu YJ (2009) Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab 27:444–451CrossRefPubMed Zhang ZL, He JW, Zhang H, Hu WW, Fu WZ, Gu JM, Yu JB, Gao G, Hu YQ, Li M, Liu YJ (2009) Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab 27:444–451CrossRefPubMed
18.
go back to reference Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513–1518CrossRefPubMed Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513–1518CrossRefPubMed
19.
go back to reference Pangrazio A, Pusch M, Caldana E, Frattini A, Lanino E et al (2010) Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations. Hum Mutat 31:E1071–E1080CrossRefPubMed Pangrazio A, Pusch M, Caldana E, Frattini A, Lanino E et al (2010) Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations. Hum Mutat 31:E1071–E1080CrossRefPubMed
20.
go back to reference Benichou O, Laredo J, De Vernejoul M (2000) Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients. Bone 26:87–93CrossRefPubMed Benichou O, Laredo J, De Vernejoul M (2000) Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients. Bone 26:87–93CrossRefPubMed
21.
go back to reference Chu K, Koller DL, Snyder R, Fishburn T, Lai D, Waguespack SG, Foroud T, Econs MJ (2005) Analysis of variation in expression of autosomal dominant osteopetrosis type 2: searching for modifier genes. Bone 37:655–661CrossRefPubMed Chu K, Koller DL, Snyder R, Fishburn T, Lai D, Waguespack SG, Foroud T, Econs MJ (2005) Analysis of variation in expression of autosomal dominant osteopetrosis type 2: searching for modifier genes. Bone 37:655–661CrossRefPubMed
22.
go back to reference Campos-Xavier AB, Casanova JL, Doumaz Y, Feingold J, Munnich A, Cormier-Daire V (2005) Intrafamilial phenotypic variability of osteopetrosis due to chloride channel 7 (CLCN7) mutations. Am J Med Genet A 133A:216–218CrossRefPubMed Campos-Xavier AB, Casanova JL, Doumaz Y, Feingold J, Munnich A, Cormier-Daire V (2005) Intrafamilial phenotypic variability of osteopetrosis due to chloride channel 7 (CLCN7) mutations. Am J Med Genet A 133A:216–218CrossRefPubMed
23.
go back to reference Chu K, Snyder R, Econs MJ (2006) Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties. J Bone Miner Res 21:1089–1097CrossRefPubMed Chu K, Snyder R, Econs MJ (2006) Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties. J Bone Miner Res 21:1089–1097CrossRefPubMed
24.
go back to reference Sulewska A, Niklinska W, Kozlowski M, Minarowski L, Naumnik W, Niklinski J, Dabrowska K, Chyczewski L (2007) DNA methylation in states of cell physiology and pathology. Folia Histochem Cytobiol 45:149–158PubMed Sulewska A, Niklinska W, Kozlowski M, Minarowski L, Naumnik W, Niklinski J, Dabrowska K, Chyczewski L (2007) DNA methylation in states of cell physiology and pathology. Folia Histochem Cytobiol 45:149–158PubMed
Metadata
Title
Two novel mutations of CLCN7 gene in Chinese families with autosomal dominant osteopetrosis (type II)
Authors
Hui Zheng
Chong Shao
Yan Zheng
Jin-Wei He
Wen-Zhen Fu
Chun Wang
Zhen-Lin Zhang
Publication date
01-07-2016
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 4/2016
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-015-0682-2

Other articles of this Issue 4/2016

Journal of Bone and Mineral Metabolism 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.